Suggestions
Toby Wilson Waterworth
Internationally versatile Board member and senior executive with broad experience of developing biopharmaceutical and healthcare companies.
Toby Wilson Waterworth is the CEO & Chairman of Ambrose Healthcare Ltd, a specialist pharmaceutical company focused on developing treatments for rare diseases and unmet medical needs.12 With over 30 years of experience in the life sciences industry, Toby has a proven track record of success in developing and commercializing technology-based businesses internationally.13
Professional Background
Leadership Roles::
- CEO & Chairman at Ambrose Healthcare Ltd (March 2023 - present)15
- Founder & Non-Executive Director of CamStent Ltd
- Chief Executive Officer of Atlantic Healthcare plc (2006 - 2022)5
- Director at Parker Davies Lande1
Expertise:: Toby specializes in leading and being part of leadership teams in life science companies. He has been involved in ventures that have generated close to $1 billion in shareholder value.3
Achievements and Qualifications
- Fellow of the Royal Society of Medicine3
- Fellow Chartered Accountant (Institute of Chartered Accountants in England & Wales)13
- Led Atlantic Healthcare, which delivered 30x value for early investors3
- Raised $50M in equity and grants for a previous venture, building a diversified late-stage clinical pipeline valued at $500M by a top 4 Accountancy firm2
Industry Involvement
Toby holds leadership roles in organizations such as:
- MIT Enterprise Forum
- British Government's UK Trade and Investment Catalyst Programme1
Colleagues describe Toby as a "brilliant CFO" and a "true deal-maker," praising his dedication to the success of his ventures.4
Highlights
In the 10 years before diagnosis, rare disease patients cost the NHS twice as much as other patients. The ratio is higher for patients under 10 years old. (Source: Imperial College London). One in two patients diagnosed rare disease is a child, and unfortunately 30% of children with a rare disease do not reach the age of five.
And there are only approved treatments for 5% of rare diseases, so it’s likely that with current approaches the high healthcare costs will continue as they did pre-diagnosis.
Traditionally, it’s been hard to develop pharmaceutical treatments for rare diseases using financial business models that work for blockbuster drugs.
So that’s not what we are doing at Ambrose Healthcare. We’re developing new more economic models designed for rare diseases, to get safe and effective therapies into the hands of patients and onto the market, more quickly and cost-effectively.
Human to human it makes sense. And we believe financially it does too.
Interested in talking to me about Ambrose Healthcare? We’ve got a few last opportunities to be one of Ambrose’s ground floor investors and help to make a difference.
P.S. Treatments for rare disease represent one of the fastest growing pharmaceutical niches, with a current CAGR of 12.8%. If we can get new treatments into the hands of patients more quickly and cost-effectively, and provide investors attractive returns in the process, then just maybe we can accelerate the rate at which new treatments are developed and help to close the gap on the 95% of rare diseases that currently have no approved drug therapy.
Ambrose Healthcare is finalising it’s first funding round, while also preparing for the next, larger round. To get involved or talk about rare disease drug development, please get in touch.
You can also sign-up to our newsletter to stay up to date and be the first to know when our next whitepaper drops this September.
#RareDisease #DrugDevelopment #HealthInnovation #AmbroseHealthcare #Investment #Seedround #rarediseasepatients #patientcentric #pharmaceuticals #finance #economics Imperial College London
Talking about finance and healthcare can be hard. How can we put a price on health? However, the thing is, it’s a delicate balancing act. If a therapeutic treatment works, but the finances don’t - products get shelved. For me, at Ambrose, it’s not about big profits, it’s about making sure that treatments that improve outcomes, are readily and continuously available, at a price that patients and payers can benefit from. I’ve had the privilege to witness the elation that a new, effective rare disease drug treatment can bring to individuals who had given up hope. And the devastation when a healthcare provider will not pay for a drug, and when a drug is no longer available. And there are promising drug assets sitting on the shelf, that have the potential to benefit rare disease patients, waiting to be dusted down and made available for patients. So at Ambrose, we’re not focusing on breakthrough science and discovery of new molecules. We’re using our expertise to match patient needs with existing drugs treatments, that are just waiting for their chance to shine. Their chance to show how they can change lives . And we are aiming to do it a drug price that can deliver benefits to patients and is attractive to payers. We’ve already got the rights to the first two of these types of products. And now, we are on a mission to close our first equity investment round, so we can focus on shepherding these potential treatments through the next stages of clinical development, provide the opportunity for early treatment access enabled by international Named Patient Supply regulations, and bring on others. We can’t change the world for everyone, but we hope to change some people’s worlds. --- Ambrose Healthcare is led by an experienced pharmaceutical team that is finalising it’s first equity funding seed round, while also preparing for the next, larger round. To get involved or talk about rare disease drug development, please get in touch.
You can also sign-up to our newsletter below to stay up to date and be the first to know when our next white paper is released this September.
#RareDisease #DrugDevelopment #HealthInnovation #Entrepreneurship #AmbroseHealthcare #rarediseasesdrugdevelopment #costofhealth #rarediseasepatients #earlyaccess #pharmaceuticals #patientcentric #drugassets #equityinvestment #pharmaceuticalteam #changetheworld #clinicaldevelopment #drugprice #payers #finance #patients #price
